| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4026168 | Ophthalmology | 2014 | 9 Pages |
Abstract
Systemic complement inhibition with eculizumab was well tolerated through 6 months but did not decrease the growth rate of GA significantly. However, there was a statistically significant correlation between the low-luminance deficit at baseline and the progression of GA over 6 months.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Zohar MD, MHA, Carlos MD, Renata Portella MD, Giovanni PhD, Fernando M. MD, PhD, Andrew A. MD, MBA, Kang MD, PhD, SriniVas MD, William MS, Philip J. MD, PhD,